FDA Expands Jaypirca Approval for Certain People With Untreated CLL and SLL
The U.S. Food and Drug Administration has expanded the approved use of Jaypirca (pirtobrutinib), giving certain adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) another targeted treatment option.
On October 2, 2026, the FDA approved pirtobrutinib for adults with previously untreated CLL or SLL who have no known deletion of chromosome 17p, commonly referred to as del(17p). The decision moves Jaypirca into the first-line treatment setting for appropriate patients.
The approval is particularly notable because pirtobrutinib is a non-covalent Bruton tyrosine kinase, or BTK, inhibitor. It works differently from earlier covalent BTK inhibitors and has already established a role for patients with CLL or SLL whose disease has returned or stopped responding after previous BTK inhibitor treatment.
What the New Jaypirca Approval Means
CLL is a blood cancer involving abnormal lymphocytes, a type of white blood cell. SLL is closely related and is considered the same disease biologically, but the cancer cells are found mainly in the lymph nodes rather than predominantly in the blood.
For some people with CLL or SLL, treatment may not be necessary immediately after diagnosis. When treatment is required, however, selecting an effective first-line therapy can be an important decision.
The new FDA approval means that Jaypirca can now be considered for adults who have previously untreated CLL or SLL without a known 17p deletion. This does not mean that pirtobrutinib is appropriate for every newly diagnosed patient. Treatment decisions depend on individual disease characteristics, overall health, previous medical history and other factors.
The FDA's decision was supported by results from the Phase 3 BRUIN CLL-313 clinical trial.
BRUIN CLL-313 Trial Showed Significant Progression-Free Survival Benefit
BRUIN CLL-313 was a randomized Phase 3 study involving 282 previously untreated patients with CLL or SLL without del(17p).
Participants were randomly assigned to receive either pirtobrutinib or bendamustine plus rituximab, a chemoimmunotherapy combination.
After a median follow-up of approximately 28 months, the study found a significant improvement in progression-free survival with pirtobrutinib.
The median progression-free survival had not yet been reached in the pirtobrutinib group, compared with 33.5 months in the bendamustine plus rituximab group. The hazard ratio was 0.20, indicating an approximately 80% reduction in the relative risk of disease progression or death compared with the study's control treatment.
The published study in Journal of Clinical Oncology reported a 24-month progression-free survival rate of 93.4% with pirtobrutinib compared with 70.7% with bendamustine plus rituximab.
These findings formed an important part of the evidence supporting the FDA's expanded indication.
Response Rates Also Favored Pirtobrutinib
The BRUIN CLL-313 results showed that pirtobrutinib produced a high overall response rate.
According to the study results, the overall response rate assessed by an independent review committee was approximately 94% with pirtobrutinib, compared with 81% with bendamustine plus rituximab.
Responses included both complete and partial responses. However, response rate alone does not determine whether a treatment is the best option for an individual patient. Physicians also consider progression-free survival, overall survival, treatment duration, side effects, other medical conditions and patient preferences.
The published trial also reported fewer treatment-related dose reductions and treatment discontinuations because of adverse events in the pirtobrutinib group than in the bendamustine plus rituximab group.
Why Non-Covalent BTK Inhibition Matters
BTK is an important protein involved in signaling pathways that help certain B cells survive and multiply. Blocking BTK can therefore interfere with the growth and survival of malignant B cells.
Pirtobrutinib belongs to a newer class of non-covalent BTK inhibitors. Unlike covalent BTK inhibitors, which bind permanently to BTK at a specific site, pirtobrutinib uses a reversible binding mechanism.
This difference has attracted significant interest in hematology because BTK biology can change during treatment, including changes involving the C481 position of the BTK protein.
Jaypirca has already been used in certain patients with relapsed or refractory CLL or SLL who have previously received a covalent BTK inhibitor. The new approval brings the medicine into an earlier stage of the treatment journey for selected patients.
Safety Remains an Important Consideration
While the BRUIN CLL-313 findings are encouraging, pirtobrutinib is not without risks.
The FDA-approved information includes warnings and precautions concerning infections, bleeding, cytopenias, cardiac arrhythmias, second primary malignancies, liver toxicity and embryo-fetal toxicity.
In clinical studies, serious infections have occurred in patients receiving Jaypirca. Pneumonia was among the serious adverse reactions reported. Blood count abnormalities, including decreases in neutrophils, platelets and hemoglobin, can also occur.
Cardiac arrhythmias, including atrial fibrillation and atrial flutter, have been reported. Patients and healthcare professionals should also be alert to symptoms that could indicate bleeding or liver injury.
Because of these potential risks, treatment with pirtobrutinib requires medical supervision and appropriate monitoring.
Jaypirca's Growing Role in CLL Treatment
The latest FDA action adds to the expanding clinical development program surrounding pirtobrutinib.
The BRUIN program has evaluated the medicine across different stages of CLL and SLL treatment. Studies have investigated pirtobrutinib in previously untreated patients, patients who have received other BTK inhibitors and patients receiving combination treatment.
BRUIN CLL-313 is particularly significant because it was designed specifically to evaluate a non-covalent BTK inhibitor in previously untreated CLL/SLL. The results were published in Journal of Clinical Oncology in 2026.
Researchers and clinicians are continuing to study how pirtobrutinib may fit alongside other modern targeted therapies.
What This Could Mean for Patients
For people who require first-line treatment for CLL or SLL and meet the FDA-approved criteria, the expanded indication provides another treatment option.
The development also reflects the broader transformation of CLL care. Treatment has increasingly moved away from traditional chemoimmunotherapy toward targeted medicines designed to interfere with specific biological pathways involved in cancer growth.
However, no single treatment is right for everyone. Genetic findings, including del(17p), overall health, age, cardiovascular history, kidney and liver function, medication interactions and individual treatment goals can all influence therapy selection.
Patients should discuss the potential benefits and risks of Jaypirca with a qualified hematologist or oncologist before making treatment decisions.
Final Takeaway
The FDA's October 2026 approval expands the role of Jaypirca (pirtobrutinib) into first-line treatment for certain adults with previously untreated CLL or SLL without a known 17p deletion.
The decision is supported by the BRUIN CLL-313 Phase 3 trial, in which pirtobrutinib significantly improved progression-free survival compared with bendamustine plus rituximab.
For the CLL community, the approval represents another step toward more targeted and individualized cancer treatment. Continued research will help clarify how pirtobrutinib should be positioned among the growing number of available therapies.
Disclaimer: This article is intended for general educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Jaypirca (pirtobrutinib) can cause serious and potentially life-threatening side effects. Patients should consult a qualified healthcare professional for advice about CLL, SLL, pirtobrutinib, or any other treatment.